nCounter NanoString Assay Shows Variable Concordance With Immunohistochemistry-based Algorithms in Classifying Cases of Diffuse Large B-Cell Lymphoma According to the Cell-of-Origin.


Journal

Applied immunohistochemistry & molecular morphology : AIMM
ISSN: 1533-4058
Titre abrégé: Appl Immunohistochem Mol Morphol
Pays: United States
ID NLM: 100888796

Informations de publication

Date de publication:
10 2019
Historique:
pubmed: 5 9 2018
medline: 20 6 2020
entrez: 5 9 2018
Statut: ppublish

Résumé

Classifying diffuse large B-cell lymphoma (DLBCL) according to the cell-of-origin (COO) was first proposed using gene expression profiling; accordingly, DLBCL is classified into germinal-center B-cell type and activated B-cell type. Immunohistochemistry (IHC)-based classification using different algorithms is used widely due to the ability to use formalin-fixed paraffin-embedded tissue. Recently, newer techniques using RNA expression from formalin-fixed paraffin-embedded were introduced including the nCounter NanoString platform assay. In this brief report, we study the degree of concordance between the NanoString assay and 6 commonly utilized IHC-based algorithms to classify DLBCL cases by COO. Stains for CD10, BCL2, BCL6, FOXP-1, MUM-1, and LOM2 were used to classify a cohort of DLBCL by COO according to the respective IHC-algorithms. Then, RNA was extracted from the same cases for NanoString assay classification. The degree of concordance was calculated between the NanoString classification and each IHC-algorithm as well as among the different IHC-algorithm themselves. The concordance in COO classification of DLBCL between NanonoString assay and IHC-based algorithms is variable depending on the used IHC-algorithm; the highest concordance is seen with the Visco algorithm (κ=0.69; P=0.001). Therefore, discrepancies between the recently introduced NanoString assay and the commonly utilized IHC-algorithms are expected to some extent and should be taken into consideration when interpreting conflicting results.

Identifiants

pubmed: 30179888
doi: 10.1097/PAI.0000000000000696
doi:

Substances chimiques

BCL6 protein, human 0
Biomarkers, Tumor 0
Proto-Oncogene Proteins c-bcl-2 0
Proto-Oncogene Proteins c-bcl-6 0
RNA 63231-63-0
Neprilysin EC 3.4.24.11

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

644-648

Auteurs

Ali G Saad (AG)

Department of Pathology, University of Tennessee Health Science Center and Le Bonheur Children's Hospital, Memphis, TN.

Zakaria Grada (Z)

Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA.

Barbara Bishop (B)

Department of Pathology, University of Louisville, Louisville, KY.

Hend Abulsayen (H)

Departments of Pediatrics and Neurology, SUNY Downstate, Brooklyn.

Mohamed Hassan (M)

Department of Surgery, Tulane University, New Orleans, LA.

Adolfo Firpo-Betancourt (A)

Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY.

Julie Teruya-Feldstein (J)

Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY.

Mostafa Fraig (M)

Department of Pathology, University of Louisville, Louisville, KY.

Siraj M El Jamal (SM)

Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH